Tags

Type your tag names separated by a space and hit enter

Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women.
Climacteric. 2009 Jun; 12(3):248-58.C

Abstract

BACKGROUND

Although a number of studies have evaluated the associations between use of postmenopausal hormone therapy (HT) and mammographic density, few have assessed the effects of the medications containing estradiol (E2) plus norethisterone acetate (NETA). In particular, there are few data on the effects of the low-dose E2/NETA regimen.

METHODS

We included data from 724 women, aged 50-70 years, residing in south-east Norway, who participated in a cross-sectional study conducted within the Norwegian Breast Cancer Screening Program. We assessed mammographic density using a previously validated computer-assisted method.

RESULTS

After adjusting for age at screening, number of children and body mass index, women who currently used HT had 6.0% higher percent mammographic density than never-users, p < 0.0001. Women who used either low- or high-dose continuous combined E2/NETA regimens had 7.7% (p < 0.0001) and 8.8% (p < 0.0001) higher percent mammographic density than never-users, respectively.

CONCLUSION

Our study suggests that the effect of E2/NETA regimens on mammographic density could be at least as detrimental to the breast tissue as several other estrogen + progestin regimens. Our results suggest that both low- and high-dose E2/NETA influence mammographic density, but there were some indications in our analyses that the effect of low-dose E2/NETA could be slightly lower than that of the older high-dose regimen.

Authors+Show Affiliations

Department of Nutrition, University of Oslo, Oslo, Norway.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19387884

Citation

Stuedal, A, et al. "Postmenopausal Hormone Therapy With Estradiol and Norethisterone Acetate and Mammographic Density: Findings From a Cross-sectional Study Among Norwegian Women." Climacteric : the Journal of the International Menopause Society, vol. 12, no. 3, 2009, pp. 248-58.
Stuedal A, Ma H, Bjørndal H, et al. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. Climacteric. 2009;12(3):248-58.
Stuedal, A., Ma, H., Bjørndal, H., & Ursin, G. (2009). Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. Climacteric : the Journal of the International Menopause Society, 12(3), 248-58. https://doi.org/10.1080/13697130802638458
Stuedal A, et al. Postmenopausal Hormone Therapy With Estradiol and Norethisterone Acetate and Mammographic Density: Findings From a Cross-sectional Study Among Norwegian Women. Climacteric. 2009;12(3):248-58. PubMed PMID: 19387884.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. AU - Stuedal,A, AU - Ma,H, AU - Bjørndal,H, AU - Ursin,G, PY - 2009/4/24/entrez PY - 2009/4/24/pubmed PY - 2009/8/21/medline SP - 248 EP - 58 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric VL - 12 IS - 3 N2 - BACKGROUND: Although a number of studies have evaluated the associations between use of postmenopausal hormone therapy (HT) and mammographic density, few have assessed the effects of the medications containing estradiol (E2) plus norethisterone acetate (NETA). In particular, there are few data on the effects of the low-dose E2/NETA regimen. METHODS: We included data from 724 women, aged 50-70 years, residing in south-east Norway, who participated in a cross-sectional study conducted within the Norwegian Breast Cancer Screening Program. We assessed mammographic density using a previously validated computer-assisted method. RESULTS: After adjusting for age at screening, number of children and body mass index, women who currently used HT had 6.0% higher percent mammographic density than never-users, p < 0.0001. Women who used either low- or high-dose continuous combined E2/NETA regimens had 7.7% (p < 0.0001) and 8.8% (p < 0.0001) higher percent mammographic density than never-users, respectively. CONCLUSION: Our study suggests that the effect of E2/NETA regimens on mammographic density could be at least as detrimental to the breast tissue as several other estrogen + progestin regimens. Our results suggest that both low- and high-dose E2/NETA influence mammographic density, but there were some indications in our analyses that the effect of low-dose E2/NETA could be slightly lower than that of the older high-dose regimen. SN - 1473-0804 UR - https://www.unboundmedicine.com/medline/citation/19387884/Postmenopausal_hormone_therapy_with_estradiol_and_norethisterone_acetate_and_mammographic_density:_findings_from_a_cross_sectional_study_among_Norwegian_women_ L2 - http://www.tandfonline.com/doi/full/10.1080/13697130802638458 DB - PRIME DP - Unbound Medicine ER -